Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) LT-Debt-to-Total-Asset : 0.31 (As of Jun. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Santhera Pharmaceuticals Holding AG's long-term debt to total assests ratio for the quarter that ended in Jun. 2023 was 0.31.

Santhera Pharmaceuticals Holding AG's long-term debt to total assets ratio declined from Jun. 2022 (0.32) to Jun. 2023 (0.31). It may suggest that Santhera Pharmaceuticals Holding AG is progressively becoming less dependent on debt to grow their business.

Santhera Pharmaceuticals Holding AG LT-Debt-to-Total-Asset Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG LT-Debt-to-Total-Asset Chart

Santhera Pharmaceuticals Holding AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.50

0.51

0.67

0.30

0.34

Santhera Pharmaceuticals Holding AG Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.21	0.30	0.32	0.34	0.31

Santhera Pharmaceuticals Holding AG LT-Debt-to-Total-Asset Calculation

Santhera Pharmaceuticals Holding AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	23.279	/	68.405
	=	0.34

Santhera Pharmaceuticals Holding AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (Q: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2023 )	/	Total Assets (Q: Jun. 2023 )
	=	21.679	/	70.052
	=	0.31

Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Santhera Pharmaceuticals Holding AG LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

SANNz:UK SANN:Switzerland

Address

Hohenrainstrasse 24, Pratteln, CHE, 4133

Website

https://www.santhera.com

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.